This report identifies 18 specific medicines that want to be listed in Australia but have been deterred by processes and declining investment in the Pharmaceutical Benefits Scheme (PBS). It finds that Australia’s current policy and medicines funding environment is contributing to a growing number of missing medicines and innovative therapies available in other high-income countries.

This report identifies emerging trends across sectors – including health technology, disability advocacy, construction, HVAC, and digital and energy technologies – likely to impact the future energy system and residential sector. Drawing on a review of 93 reports, interviews with 20 experts, and ethnographic qualitative research, it has a particular focus on implications for residential...

Australia’s Health Technology Assessment system uses comparative evaluation to determine the value of medicines against a relevant comparator. Comparator selection has increasingly defaulted to the lowest cost comparator. This analysis finds that the lowest cost comparator use has become systemic, creating structural barriers to patient access. It provides a phased roadmap proposing eight actions.

Australia’s health system is a major contributor to national greenhouse gas emissions. One way to address this is to consider the environmental impacts of healthcare in health technology assessments (HTA) and decision-making processes. This issues brief provides insights on how integrating environmental impacts into HTAs can contribute to a more environmentally sustainable healthcare system.

Centred around four key actions and five key priority sectors, the statement includes a raft of initiatives designed to make it easier, simpler and faster to do business in Victoria. The four key actions are: open doors, cut red tape, build new skills and reach every community. The statement is aimed at stimulating innovation and...